CHILD INFECTIONS AND IMMUNIZATION PROBLEMS IN ADULTS. EXPERIENCE OF THE FAMILY VACCINAL PREVENTION CENTER
https://doi.org/10.15690/pf.v10i2.641
Abstract
About the Authors
M. G. GalitskayaRussian Federation
MD, head of the vaccinal prevention department at the RAMS SCCH
L. S. Namazova-Baranova
Russian Federation
N. E. Tkachenko
Russian Federation
M. V. Fedoseenko
Russian Federation
V. V. Botvinyeva
Russian Federation
F. C. Shakhtatinskaya
Russian Federation
References
1. Available at: http://www.cdc.gov/vaccines
2. Adult vaccination strategies in Europe — an overview from a VENICE II project. Elisabeth E. Kanitz, Istituto Superiore di Sanita. Rome, Italy. ESCAIDE, November 2010.
3. Meditsinskaya virusologiya: Rukovodstvo. Pod red. D.K. L'vova [Clinical Virusology. Guideline. Edited by D.K. L'vov]. Moscow, «Meditsinskoe informatsionnoe agentstvo», LLC, 2008. 656 p.
4. Kostinov M.P. Immunokorrektsiya vaktsinal'nogo protsessa u lits s narushennym sostoyaniem zdorov'ya [Immunotherapy Vaccination Process in Patients with Impaired Health]. Moscow, 2006. pp. 69–85.
5. Botvin'eva V.V., Galitskaya M.G., Rodionova T.V., Tkachenko N.E., Namazova-Baranova L.S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011; 8 (1): 6–10.
6. Virusnye gepatity. Sbornik normativno-metodicheskikh materialov [Viral Hepatitis. Collection of Normative and Methodological Materials]. Moscow, Grant", 1998. 128 p.
7. Moskovskaya I.A. Bolezni pecheni u detei. Pod red. akad. RAMN, prof. M.Ya. Studenikina [Liver Disease in Children. Edited by acad. RAMS, prof. M.Ya. Studenikin]. Tula, Grif i K, 2007. 536 p.
8. Dupuy Y. M., Kostewics E., Alagille D. Hepatitis b in children. Analysis of 80 cases of acute and chronic hepatitis b. J. Pediatr. 1978; 72 (1): 17–20.
9. Tong M. Y., Thurnsby M., Rakela J., McPeak C., Edwards V. M., Mosley J. W. Studies on maternal-infant transmission of the viruses with acute hepatitis. Gastroenterology. 1981; 80 (5): 999–1004.
10. Molochnyi V.P., Protasenya I.I. Gepatity u detei [Hepatitis in Children]. Khabarovsk, Izd-vo Dal'nevostochnogo meditsinskogo universiteta, 2004. 148 p.
11. Shakhgil'dyan I.V., Mikhailov M.I., Onishchenko G.G. Parenteral'nye virusnye gepatity (epidemiologiya, diagnostika, profilaktika) [Parenteral Viral Hepatitis (Epidemiology, Diagnosis, Prevention)]. Moscow, GOU VUNMTs MZ RF, 2003. 384 p.
12. Baranov A.A., Namazova-Baranova L.S., Galitskaya M.G. Bolezni detskogo vozrasta ot A do Ya [Child Diseases from A to Z]. Moscow, Pediatr", 2012. p. 16.
13. Tatochenko V.K., Ozeretskovskii N.A., Fedorov A.M. Immunoprofilaktika-2011 (spravochnik) [Immunization-2011 (Reference)]. Moscow, 2011. p. 198.
14. Mackie C. O., Buxton J. A., Tadwalkar S., Patrick D. M. Hepatitis B immunization strategies: timing is everything. CMAJ. 2009; 180 (2): 16–202.
15. Andre F. E. Effectiveness of newborn hepatitis B vaccination programmes in achieving a reduction of chronic carriage — timing of the birth dose — Administration of big: review. CDC — UNICEF — VHPB — WHO meeting report Istanbul. 2006.
16. Medunitsyn N.V. Vaktsinologiya. Izd. 2-e, pererab. i dop [Vaccinology. 2nd edition, revised and enlarged]. Moscow, Triada-Kh, 2004. 448 p.
17. Mikhailov M.I., Shakhgil'dyan I.V., Onishchenko G.G. Enteral'nye virusnye gepatity (etiologiya, epidemiologiya, diagnostika, profilaktika) [Enteral Viral Hepatitis (Etiology, Epidemiology, Diagnosis, Prevention)]. Moscow, FGOU «VUNMTs Roszdrava», 2007. 352 p.
18. Shakhgil'dyan I.V., Mikhailov M.I., Ershova O.N. et al. Zhurnal E i V = Journal E&V. 2011; 2: 51–52.
19. Uchaikin V.F., Nisevich N.I., Cherednichenko T.V. Virusnye gepatity ot A do TTV u detei [Viral Hepatitis A to TTV in Children]. Moscow, «Izdatel'stvo Novaya Volna», LLC, 2003. p. 25.
20. Epidemiology of hepatitis A. Morbidity and Mortality Weekly Report (MMWR). 2006; 55 (7): 2–8.
21. Andre F., Van Damme P., Safary A., Banatvala J. Infected hepatitis A vaccine: immunogenicity, efficacy. Safety and reviw of official recommendation for use. Expert Rev. 2002; 1 (1): 9–23.
22. «Ob utverzhdenii regional'nogo kalendarya profilakticheskikh privivok i profilakticheskikh privivok po epidemicheskim pokazaniyam». Prikaz Departamenta zdravookhraneniya goroda Moskvy ot 31 marta 2011 g. № 271 ["About Approval of the Regional Vaccination Calendar and Prophylactic Immunization on Epidemic Indications." Order of the Moscow Health Department dated March 31, 2011 № 271.]
23. Galitskaya M.G. Voprosy sovremennoi pediatrii = Current pediatrics. 2010; 9 (5): 99–102.
24. Nathwani D., Maclean A., Conway S., Carrington D. Varicella infections in pregnancy and the newborn. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British society for the study of infection. J. Infect. 1998; 36 (Suppl. 1): 59–71.
25. Baranov A.A., Balashov D.N., Gorelov A.V. et al. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2008; 5 (3): 6–14.
26. Kostinov M.P. Vaktsinatsiya detei s narushennym sostoyaniem zdorov'ya. Prakticheskoe rukovodstvo dlya vrachei [Vaccination of Children with Impaired Health. A Practical Guide for Physicians] Moscow, 2002, pp. 7-9, 12-15, 19, 103-104.
27. Galitskaya M.G. Nauchnoe obosnovanie novykh podkhodov k vaktsinoprofilaktike grippa u detei i chlenov ikh semei. Avtoref. dis. … kand. med. nauk [Scientific Substantiation of New Approaches to Vaccine Preventable Influenza in Children and their Families. Author’s abstract]. Moscow, 2007.
28. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2012; 61 (40).
29. Chuchalin A.G. Vnebol'nichnye pnevmonii u vzroslykh: prakticheskie rekomendatsii po diagnostike, lecheniyu i profilaktike [Community-acquired Pneumonia in Adults: Guidelines for Diagnosis, Treatment and Prevention]. Moscow, 2010, pp 106.
30. Food and Drug Administration. Vaccines: approved products. Prevnar 13 (pneumococcal 13-valent conjugate vaccine). Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/Approved Products/ucm201667.htm, accessed March 2012.20). EMA Oct 2011: European public assessment report (EPAR) for PCV10 (First published in May 2009, last updated in October 2011). EMA 562289/2011.
31. Mayanskii N.A., Alyab'eva N.M., Katosova L.K., Grechukha T.A., Pinelis V.G., Namazova-Baranova L.S. Voprosy diagnostiki v pediatrii = Problems of diagnosis in pediatrics. 2010; 2 (6): 6–10.
32. European Medicines Agency (EMA) Available at: http://www.ema.europa.eu/home. WHO position paper on pneumococcal vaccines/Weekly epidemiological record, No. 14, 6 Аpril 2012/www.who.wer.int
33. Collins S., Mazloomzadeh S., Winter H., Blomfield P., Bailey A., Young L. S., Woodman C. B. J. High incidence of the cervical human papillomavirus infection in women during their fi rst sexual relationship. Br. J. Obstet. Gynaecol. 2002; 109: 96–98.
34. de Sanjose S., Diaz M., Castellsague X., Clifford G., Bruni L., Munoz N., Bosch F. X. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 2007; 7: 453–59.
35. Olsson S.-E., Villa L. L., Costa R. et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-likeparticle vaccine. Vaccine. 2008; 25: 4931–39.
36. Profilaktika raka sheika matki: Rukovodstvo dlya vrachei. Pod red. akad. RAMN G. T. Sukhikh, prof. V. N. Prilepskoi. 3-e izd., pererab. i dop. Glava 7. Namazova-Baranova L. S., Krasnopol'skii V. I., Sukhikh G. T., Prilepskaya V. N., Zarochentseva N.V., Galitskaya M.G. Vaktsinoprofilaktika raka sheiki matki [Cervical Cancer Prevention.Manual for Physicians. Edited by RAMS acad. G.T. Sukhikh, prof. V.N. Prilepskaya. 3rd edition, revised and enlarged. Chapter 7. Namazova-Baranova L. S., Krasnopol'skii V. I., Sukhikh G. T., Prilepskaya V. N., Zarochentseva N.V., Galitskaya M.G. Vaccine Prevention of Cervical Cancer.]. Moscow, MEDpressinform, 2012. 192 p.
37. Munoz N., Mendez F., Posso H., Molano M., van den Brule A. J., Ronderos M., Meijer C., Munoz A. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J. Infect. Dis. 2004; 15: 2077–87.
38. Namazova-Baranova L.S., Galitskaya M.G., Fedoseenko M.V., Gaivoronskaya A.G., Aleksina S.G. Pediatricheskaya farmakologiya = Pediatric. pharmacology. 2008; 5 (4): 20–24.
39. Insinga R. P., Dasbach E. J., Elbasha E. H., Liaw K. L., Barr E. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect. Agent Cancer. 2007; 2: 15.
40. Galitskaya M.G., Namazova-Baranova L.S. Pediatricheskaya farmakologiya = Pediatric. pharmacology. 2011; 8 (4): 82–86.
41. Munoz N., Bosch F. X., Castellsague X., Diaz M., de Sanjose S., Hammouda D. et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer. 2004; 111: 278–285.
42. Instruktsiya po primeneniyu vaktsiny Tservariks (Registratsionnoe udostoverenie LRS 006423/08, obnovlenie instruktsii ot 15.02.2013 g.) [Application of the Vaccine Cervarix (Registration Certificate RL 006423/08, update instructions from 15.02.2013 year)].
Review
For citations:
Galitskaya M.G., Namazova-Baranova L.S., Tkachenko N.E., Fedoseenko M.V., Botvinyeva V.V., Shakhtatinskaya F.C. CHILD INFECTIONS AND IMMUNIZATION PROBLEMS IN ADULTS. EXPERIENCE OF THE FAMILY VACCINAL PREVENTION CENTER. Pediatric pharmacology. 2013;10(2):24-32. https://doi.org/10.15690/pf.v10i2.641